Download PDF
Semin Liver Dis 2009; 29(4): 348-356
DOI: 10.1055/s-0029-1240003
© Thieme Medical Publishers

Causality Assessment in Drug-Induced Liver Injury

Paul H. Hayashi1
  • 1UNC Liver Program, Department of Medicine, Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina
Further Information

Publication History

Publication Date:
13 October 2009 (online)

    Permissions and Reprints

ABSTRACT

Assigning causality in drug-induced liver injury (DILI) due to a particular medication or herbal and dietary supplement relies on clinical history, exclusion of competing causes, prior reports of DILI, and judgment—no objective laboratory or histological tests exist to confirm a diagnosis of suspected DILI. Current causality assessment instruments are based on algorithmic scoring systems but are not widely used. Expert opinion remains the gold standard, but is cumbersome and has limited reproducibility. The lack of a valid and widely available causality assessment method hinders the identification of genetic and biochemical markers that may help better define DILI. Emerging technologies in pharmacogenomics and toxicogenomics may identify such markers if well-defined DILI cases and controls can provide tissue samples for analysis. In this article, current causality assessment instruments, including expert opinion, are discussed, and the necessary features for an improved instrument are provided.

KEYWORDS

Hepatotoxicity - dietary supplements - expert opinion - adverse drug reactions

REFERENCES

  • 1 Temple R J. Hepatotoxicity through the years: Impact on the FDA. Available at: http://www.fda.gov/cder/livertox/Presentations/im1389/sld002.htm Accessed May 23, 2009
    PubMedGoogle Scholar
  • 2 Temple R J, Himmel M H. Safety of newly approved drugs: implications for prescribing.  JAMA. 2002;  287(17) 2273-2275
    CrossrefPubMedGoogle Scholar
  • 3 Lee W M, Squires Jr R H, Nyberg S L, Doo E, Hoofnagle J H. Acute liver failure: Summary of a workshop.  Hepatology. 2008;  47(4) 1401-1415
    CrossrefPubMedGoogle Scholar
  • 4 Bissell D M, Gores G J, Laskin D L, Hoofnagle J H. Drug-induced liver injury: mechanisms and test systems.  Hepatology. 2001;  33(4) 1009-1013
    CrossrefPubMedGoogle Scholar
  • 5 Stephens M D. The diagnosis of adverse medical events associated with drug treatment.  Adverse Drug React Acute Poisoning Rev. 1987;  6(1) 1-35
    PubMedGoogle Scholar
  • 6 Arimone Y, Miremont-Salamé G, Haramburu F et al.. Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions.  Br J Clin Pharmacol. 2007;  64(4) 482-488
    CrossrefPubMedGoogle Scholar
  • 7 Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge.  J Clin Epidemiol. 1993;  46(11) 1331-1336
    CrossrefPubMedGoogle Scholar
  • 8 Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries.  J Clin Epidemiol. 1993;  46(11) 1323-1330
    CrossrefPubMedGoogle Scholar
  • 9 Maria V A, Victorino R M. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis.  Hepatology. 1997;  26(3) 664-669
    CrossrefPubMedGoogle Scholar
  • 10 Watkins P B, Seeff L B. Drug-induced liver injury: summary of a single topic clinical research conference.  Hepatology. 2006;  43(3) 618-631
    CrossrefPubMedGoogle Scholar
  • 11 Fontana R J, Watkins P B, Bonkovsky H L DILIN Study Group et al. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct.  Drug Saf. 2009;  32(1) 55-68
    CrossrefPubMedGoogle Scholar
  • 12 Andrade R J, Lucena M I, Perez-Moreno J M et al.. Drug-induced hepatotoxicity: preliminary results from a surveillance program in south Spain.  J Hepatol. 1997;  26(suppl 1) 297
    PubMedGoogle Scholar
  • 13 Chalasani N, Fontana R J, Bonkovsky H L Drug Induced Liver Injury Network (DILIN) et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States.  Gastroenterology. 2008;  135(6) 1924-1934, 1934, e1–e4
    CrossrefPubMedGoogle Scholar
  • 14 Witts L J. Adverse reactions to drugs.  BMJ. 1965;  2(5470) 1081-1086
    CrossrefPubMedGoogle Scholar
  • 15 Naranjo C A, Busto U, Sellers E M et al.. A method for estimating the probability of adverse drug reactions.  Clin Pharmacol Ther. 1981;  30(2) 239-245
    CrossrefPubMedGoogle Scholar
  • 16 Kramer M S, Leventhal J M, Hutchinson T A, Feinstein A R. An algorithm for the operational assessment of adverse drug reactions. I. Background, description, and instructions for use.  JAMA. 1979;  242(7) 623-632
    CrossrefPubMedGoogle Scholar
  • 17 Busto U, Naranjo C A, Sellers E M. Comparison of two recently published algorithms for assessing the probability of adverse drug reactions.  Br J Clin Pharmacol. 1982;  13(2) 223-227
    PubMedGoogle Scholar
  • 18 García-Cortés M, Lucena M I, Pachkoria K, Borraz Y, Hidalgo R, Andrade R J. Spanish Group for the Study of Drug-induced Liver Disease (grupo de Estudio para las Hepatopatías Asociadas a Medicamentos, Geham) . Evaluation of Naranjo adverse drug reactions probability scale in causality assessment of drug-induced liver injury.  Aliment Pharmacol Ther. 2008;  27(9) 780-789
    CrossrefPubMedGoogle Scholar
  • 19 Danan G. Hepatology Working Group . Causality assessment of drug-induced liver injury.  J Hepatol. 1988;  7(1) 132-136
    CrossrefPubMedGoogle Scholar
  • 20 Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting.  J Hepatol. 1990;  11(2) 272-276
    PubMedGoogle Scholar
  • 21 Rochon J, Protiva P, Seeff L B Drug-Induced Liver Injury Network (DILIN) et al. Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury.  Hepatology. 2008;  48(4) 1175-1183
    CrossrefPubMedGoogle Scholar
  • 22 Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity.  Hepatology. 2001;  33(1) 308-310
    CrossrefPubMedGoogle Scholar
  • 23 Nesher G, Dollberg L, Zimran A, Hershko C. Hepatosplenic peliosis after danazol and glucocorticoids for ITP.  N Engl J Med. 1985;  312(4) 242-243
    PubMedGoogle Scholar
  • 24 Lasser K E, Allen P D, Woolhandler S J, Himmelstein D U, Wolfe S M, Bor D H. Timing of new black box warnings and withdrawals for prescription medications.  JAMA. 2002;  287(17) 2215-2220
    CrossrefPubMedGoogle Scholar
  • 25 Aithal G P, Rawlins M D, Day C P. Clinical diagnostic scale: a useful tool in the evaluation of suspected hepatotoxic adverse drug reactions.  J Hepatol. 2000;  33(6) 949-952
    CrossrefPubMedGoogle Scholar
  • 26 Lucena M I, Camargo R, Andrade R J, Perez-Sanchez C J, Sanchez De La Cuesta F. Comparison of two clinical scales for causality assessment in hepatotoxicity.  Hepatology. 2001;  33(1) 123-130
    CrossrefPubMedGoogle Scholar
  • 27 Arimone Y, Bégaud B, Miremont-Salamé G et al.. Agreement of expert judgment in causality assessment of adverse drug reactions.  Eur J Clin Pharmacol. 2005;  61(3) 169-173
    CrossrefPubMedGoogle Scholar
  • 28 Graham B, Regehr G, Wright J G. Delphi as a method to establish consensus for diagnostic criteria.  J Clin Epidemiol. 2003;  56(12) 1150-1156
    CrossrefPubMedGoogle Scholar
  • 29 Brinker A D, Wassel R T, Lyndly J et al.. Telithromycin-associated hepatotoxicity: clinical spectrum and causality assessment of 42 cases.  Hepatology. 2009;  49(1) 250-257
    CrossrefPubMedGoogle Scholar
  • 30 Rockey D C, Seeff L B, Freston J et al.. Comparison between expert opinion and RUCAM for assignment of causality in drug-induced liver injury.  Gastroenterology. 2007;  132(4) A-773
    PubMedGoogle Scholar
  • 31 Arimone Y, Bégaud B, Miremont-Salamé G et al.. A new method for assessing drug causation provided agreement with experts' judgment.  J Clin Epidemiol. 2006;  59(3) 308-314
    CrossrefPubMedGoogle Scholar
  • 32 Uusimaa J, Hinttala R, Rantala H et al.. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus.  Epilepsia. 2008;  49(6) 1038-1045
    CrossrefPubMedGoogle Scholar
  • 33 Mallal S, Nolan D, Witt C et al.. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir.  Lancet. 2002;  359(9308) 727-732
    CrossrefPubMedGoogle Scholar
  • 34 Hetherington S, Hughes A R, Mosteller M et al.. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir.  Lancet. 2002;  359(9312) 1121-1122
    CrossrefPubMedGoogle Scholar
  • 35 Donaldson P T, Bhatnagar P, Graham J et al.. Flucloxacillin-induced liver injury: the extended MHC 57.1 haplotype as a major risk factor.  Hepatology. 2008;  48(Suppl) 396A
    PubMedGoogle Scholar
  • 36 Lucena M I, García-Cortés M, Cueto R, Lopez-Duran J, Andrade R J. Assessment of drug-induced liver injury in clinical practice.  Fundam Clin Pharmacol. 2008;  22(2) 141-158
    CrossrefPubMedGoogle Scholar
  • 37 Kleiner D E, Chalasani N, Conjeevaram H et al.. Relationship of biochemical to histologic findings and the pathological pattern of injury among cases identified in the NIH Drug-Induced Liver Injury Network (DILIN) Study.  Gastroenterology. 2007;  132(4) A-773
    PubMedGoogle Scholar
  • 38 Zimmerman H J. The Adverse Effects of Drugs and Other Chemicals on the Liver. Philadelphia, PA; Lipponcott Williams & Wilkins 1999
    PubMedGoogle Scholar
  • 39 Rahmat J, Gelfand R L, Gelfand M C, Winchester J F, Schreiner G E, Zimmerman H J. Captopril-associated cholestatic jaundice.  Ann Intern Med. 1985;  102(1) 56-58
    PubMedGoogle Scholar
  • 40 Balistreri W F. Drug Induced Liver Injury in Children. NIH Workshop on Drug-Induced Liver Injury: Standardization of Nomenclature and Causality Assessment 2008: 25-26
    PubMedGoogle Scholar
  • 41 Squires Jr R H, Shneider B L, Bucuvalas J et al.. Acute liver failure in children: the first 348 patients in the pediatric acute liver failure study group.  J Pediatr. 2006;  148(5) 652-658
    CrossrefPubMedGoogle Scholar
  • 42 Kearns G L, Abdel-Rahman S M, Alander S W, Blowey D L, Leeder J S, Kauffman R E. Developmental pharmacology—drug disposition, action, and therapy in infants and children.  N Engl J Med. 2003;  349(12) 1157-1167
    CrossrefPubMedGoogle Scholar

Paul H HayashiM.D. M.P.H. 

UNC Liver Program, Division of Gastroenterology and Hepatology

CB#7584, 8011 Burnett-Womack Bldg., Chapel Hill, NC 27599-7584

Email: paul_hayashi@med.unc.edu

      >